在腹腔大动脉动脉瘤的新药学方法
Lídia Puertas-Umbert1,2, Rafael Almendra-Pegueros1, Francesc Jiménez-Altayó3,4
1Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain.
Clinical science (London, England : 1979)
|August 10, 2023
概括
腹腔大动脉瘤 (AAA) 是一种严重的血管疾病,缺乏有效的药物治疗. 研究正在探索新的治疗目标和策略,以管理AAA的进展和预防断裂.
科学领域:
- 血管生物学和医学 血管生物学和医学
- 心血管研究研究心血管研究
- 医学治疗学 医学治疗学
背景情况:
- 腹腔大动脉动脉瘤 (AAA) 是主动脉的逐渐扩张,是一个重要的公共卫生问题,由于破裂导致的高死亡率.
- 主要危险因素包括动脉样硬化,衰老和吸烟,但有效的药理疗法仍然缺乏.
- 目前的管理依赖于对小动脉瘤的监测和高风险患者的手术修复.
结论:
- 对于腹腔大动脉动脉瘤 (AAA) 有效的药理疗法存在着迫切的未满足的医疗需求.
- 尽管进行了广泛的研究,但目前的医疗干预措施未能阻止AAA的增长,因此需要继续探索新的策略.
- 未来的研究重点是临床前研究中发现的新治疗点,有望开发有效的AAA治疗方法.
相关概念视频
Aneurysm III: Interprofessional Care
10
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
10
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463


